Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus platinum-containing chemotherapy as neoadjuvant treatment for resectable esophageal squamous cell carcinoma
ChiCTR2000040345Phase 2Not yet recruiting
- Sponsor
- Jiaozuo No.2 People's Hospital
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Jiaozuo No.2 People's Hospital. Primary endpoint: Pathological complete remission rate. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000040345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040345.